Accelerating Cell & Gene Therapy Manufacturing Through High-Impact CDMO Partnerships In mRNA, Neoantigen & Personalised Vaccine Development
- How early, structured CDMO engagement can reduce development risk and shorten timelines for mRNA, neoantigen and personalised cancer vaccine programmes in cell & gene therapy pipelines
- Aligning process development and CMC expectations between biopharma and CDMOs to avoid scale-up failures and enable smoother translation from preclinical to commercial supply
- Defining effective partnership models for complex modalities, including tech transfer best practices, capacity planning, and managing variability in patient-specific manufacturing workflows